Shots:
- BigHat Biosciences and Eli Lilly entered into a strategic collaboration to design and develop next-generation therapeutic antibodies using BigHat’s ML-powered Milliner platform and synthetic biology wet lab
- The collaboration includes up to two antibody programs and support for BigHat’s internal pipeline, including a next-gen ADC for GI cancers entering the clinic in 2026, with BigHat retaining full global rights
- Lilly will also make an equity investment in BigHat as part of its Lilly Catalyze360 providing funding for lab space, and drug development resources
Ref: BigHat Biosciences | Image: BigHat Biosciences & Eli Lilly
Related News:- Eli Lilly Reported the Data from P-III (ACHIEVE-1) Trial Evaluating an Oral GLP-1, Orforglipron
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
